MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

PTC Therapeutics Inc

Fechado

SetorSaúde

48.23 3.63

Visão Geral

Variação de preço das ações

24h

Atual

Mín

45.44

Máximo

48.7

Indicadores-chave

By Trading Economics

Rendimento

41M

-66M

Vendas

16M

213M

EPS

-0.342

Margem de lucro

-30.907

Funcionários

939

EBITDA

3M

-47M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+42.92% upside

Dividendos

By Dow Jones

Próximos Ganhos

24 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

765M

4.3B

Abertura anterior

44.6

Fecho anterior

48.23

Sentimento de Notícias

By Acuity

31%

69%

96 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

PTC Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de dez. de 2024, 12:47 UTC

Grandes Movimentos do Mercado

PTC Therapeutics Shares Jump on Pact With Novartis

Comparação entre Pares

Variação de preço

PTC Therapeutics Inc Previsão

Preço-alvo

By TipRanks

42.92% parte superior

Previsão para 12 meses

Média 66.6 USD  42.92%

Máximo 113 USD

Mínimo 50 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para PTC Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

6

Comprar

5

Manter

1

Vender

Pontuação Técnica

By Trading Central

45.4 / 56.23Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

96 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.